Harmony Biosciences Holdings
 
 
 
 
公司概覽
業務類別 Biotechnology
業務概覽 Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), andEPX-200 (lorcaserin), among others.
公司地址 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462
電話號碼 +1 484 539-9800
傳真號碼 --
公司網頁 https://www.harmonybiosciences.com
員工數量 293
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Jeffrey M. Dayno, M.D. Chief Executive Officer, President and Director 美元 743.60K 03/04/2026
Mr. Peter Anastasiou Senior Executive Vice President and Chief Operating Officer -- 02/04/2026
Mr. Andrew Serafin Chief Strategy Officer 美元 439.21K 03/04/2026
Mr. Kumar Budur Chief Medical Officer 美元 598.00K 03/04/2026
Mr. Adam Zaeske Chief Commercial officer 美元 376.92K 03/04/2026
Mr. Stephen Mollichella Senior Vice President, Controller and Principal Financial Officer -- 16/07/2026
 
董事會成員
董事會 職務 更新日期
Mr. Jeffrey S. Aronin Chairman of the Board 03/04/2026
Mr. R. Mark Graf Independent Director 03/04/2026
Mr. Geno J. Germano Director 14/05/2026
Mr. Gary L. Sender Independent Director 03/04/2026
Dr. Andreas Wicki, PhD Independent Director 03/04/2026
Dr. Jeffrey M. Dayno, M.D. Chief Executive Officer, President and Director 03/04/2026
Mr. Troy A. Ignelzi Independent Director 02/04/2026
Ms. Linda M. Szyper Independent Director 03/04/2026
Mr. Juan A. Sabater Independent Director 03/04/2026
Mr. Ron Philip Independent Director 03/04/2026
 
所屬ETF (更新日期: 19/09/2026 03:05)
代號 名稱 佔比% ▼ 持有日期
MSSMMorgan Stanley Pathway Sm-Md Cp Eq ETF0.003%31/07/2026
ACSVAmerican Century Small Cp Val Insgts ETF0.003%31/07/2026
URTYProShares UltraPro Russell20000.003%31/07/2026
UWMProShares Ultra Russell20000.003%31/07/2026
ESSCEventide Small Cap ETF0.002%31/07/2026
FSEGFidelity Enhanced Small Cap Growth ETF0.002%31/07/2026
GRPZInvesco S&P SmallCap 600 GARP ETF0.002%31/07/2026
QSMLWisdomTree U.S. Small Cap Quality Gr0.001%31/07/2026
SXQGETC 6 Meridian Quality Growth ETF0.001%31/07/2026
AVUQAvantis U.S. Quality ETF0.001%31/07/2026
ABLSAbacus FCF Small Cap Leaders ETF0.001%31/07/2026
SAAProShares Ultra SmallCap6000.001%31/07/2026
KBFRInnovator U.S. Small Cap Mgd 10 Bfr ETF0.001%31/07/2026
SMCFThemes US Small Cp CA Flw Champ ETF0.001%31/07/2026
AVTMAvantis Total Equity Markets ETF0.0005%31/07/2026
FEACFidelity Enhanced U.S. All-Cap Eq ETF0.0004%31/07/2026
GTPEGoldman Sachs MSCI Wld Priv Eq RtTrkrETF0.0004%31/07/2026
SQLTIshares MSCI USA Small-Cap Qul Fac ETF0.0002%31/07/2026
PLTLPrincipal US Small-Cap Adptv Mlt-Fac ETF0.0002%30/09/2023
MMTMState Street® SPDR® S&P® 1500MomtTiltETF0.0002%31/07/2026
  1    2    3    4    5   6    7  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.